Page last updated: 2024-12-05

2,4-diaminotoluene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-diaminotoluene: RN given refers to unlabeled parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-diaminotoluene : An aminotoluene that is para-toluidine with an additional amino group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7261
CHEMBL ID541230
CHEBI ID34237
SCHEMBL ID15010
MeSH IDM0056811

Synonyms (131)

Synonym
BIDD:ER0683
AC-14889
(5-amino-2-methyl-phenyl)-amine
toluene-2,4-diamine
inchi=1/c7h10n2/c1-5-2-3-6(8)4-7(5)9/h2-4h,8-9h2,1h
4-methylbenzene-1,3-diamine
1,3-benzenediamine, 4-methyl-
2,4-diaminotoluene
2,4-diaminotoluene (2,4-toluene diamine)
NCGC00090717-01
95-80-7
MLS001055347
smr000673562
4-m-tolylenediamine
fourrine 94
c.i. oxidation base
developer b
developer t
fourrine m
2,4-diamino-1-toluene
c.i. oxidation base 200
developer dbj
c.i. oxidation ba se
benzofur mt
2,4-diaminotoluol
pelagol grey j
brn 2205839
azogen developer h
developer 14
nci-c023o2
zogen developer h
c.i. oxidation base 35
toluenediamine, o-
un1709
4-methyl-1,3-benzenediamine
nako tmt
zoba gke
pontamine developer tn
tertral g
1-methyl-2,4-phenylenediamine
hsdb 2849
3-amino-p-tolui dine
m-toluylendiamin [czech]
2,4-toluenediamine
nci-c02302
pelagol j
meta-tolylenediamine
m-toluenediamine
developer mc
developer mtd
ccris 202
einecs 202-453-1
ai3-03717
fouramine
renal md
2,4-tolamine
eucanine gb
developer db
fouramine j
brown for fur t
3-amino-p-toluidine
4-methyl-m-phenylenediamine
m-tolylenediamine
2,4-diamino-1-methylbenzene
developer mt-cf
ci oxidation base 35
1,3-diamino-4-methylbenzene
developer mt
tolylene-2,4-diamine
2,4-diaminotoluen [czech]
5-amino-o-toluidine
2,4-diaminotoluene, analytical standard
2,4-diaminotoluene, 98%
NCGC00090717-02
rcra waste number u221
toluenediamine
toluenes (2,4-diaminotoluene, p-nitrotoluene, 4-chloro-o-phenylenediamine
2,4-toluene diamine
D0123
chebi:34237 ,
CHEMBL541230
FT-0666393
AKOS000119800
NCGC00090717-04
NCGC00090717-03
STK941128
1,3-benzenediamine, 4-methyl-, labeled with tritium
4-methyl-1,3-benzenediamine labeled with tritium
71111-07-4
dtxsid4020402 ,
cas-95-80-7
dtxcid00402
NCGC00258962-01
NCGC00254214-01
tox21_201411
tox21_300143
BBL011285
2,4-toluylenediamine or 2,4-toluenediamine
ec 202-453-1
2,4-toluylenediamine or 2,4-toluenediamine [un1709] [poison]
4-13-00-00235 (beilstein handbook reference)
m-toluylendiamin
2,4-diaminotoluen
is1akn4hyb ,
unii-is1akn4hyb
FT-0609976
91696-44-5
F3034-0052
2,4-diaminotoluene [iarc]
toluene-2,4-diamine [hsdb]
3-amino-4-methyl-aniline
4-methyl-benzene-1,3-diamine
2,4-diamino toluene
3-amino-4-methylaniline
2,4-diamino-toluene
four amine
SCHEMBL15010
W-100157
4-methyl-1,3-phenylenediamine
2,4-tolylenediamine
un 1709
m-toluylenediamine
mfcd00007804
Z57825344
4-methyl-m-phenylenediamine, analytical standard
toluylendiamin
VS-02912
Q209195
D89597
EN300-18287
1,3-benzenediamine,4-methyl-,coupled with diazotized 4-methyl-1,3-phenylenediamine,diazotized m-phenylenediamine,diazotized m-toluidine,m-phenylenediamine and m-toluidine,acetates

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The results indicate that TDA exerts a toxic effect on spermatogenesis and appears to affect androgen action and production in the male rat."( Reproductive toxicity of 2,4-toluenediamine in the rat. 2. Spermatogenic and hormonal effects.
Bloch, E; Thysen, B; Varma, SK, 1985
)
0.27
" These results indicate that TDA is capable of reducing fertility and of exerting an inhibitory or toxic effect on spermatogenesis in the rat."( Reproductive toxicity of 2,4-toluenediamine in the rat. 1. Effect on male fertility.
Bloch, E; Thysen, B; Varma, SK, 1985
)
0.27
" The present studies were carried out to determine the toxic and immunotoxic potential of DAT."( Immunotoxicity of 2,4-diaminotoluene in female B6C3F1 mice.
Bradley, SG; Brown, RD; Burns, LA; Fuchs, BA; Holsapple, MP; Luster, MI; McCay, JA; Musgrove, DL; Stern, M; White, KL, 1994
)
0.62
"Toxicogenomics, based on the temporal effects of drugs on gene expression, is able to predict toxic effects earlier than traditional technologies by analyzing changes in genomic biomarkers that could precede subsequent protein translation and initiation of histological organ damage."( High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity.
Bito, T; Fabian, G; Farago, N; Feher, LZ; Katona, RL; Kitajka, K; Kulin, S; Nagy, LI; Puskas, LG; Tiszlavicz, L; Tubak, V, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
"Physiologically based pharmacokinetic (PBPK) modeling was used to assess the low-dose exposure of patients to the carcinogen 2, 4-toluenediamine (2,4-TDA) released from the degradation of the polyester urethane foam (PU) used in Meme silicone breast implants."( A physiologically based pharmacokinetic model for 2,4-toluenediamine leached from polyurethane foam-covered breast implants.
Bushar, HF; Hutter, JC; Luu, HM, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" In current risk assessment, oral bioavailability from a specific product is considered to be equal to bioavailability found in toxicity studies in which contaminants are usually ingested via liquids or food matrices."( Consumer product in vitro digestion model: Bioaccessibility of contaminants and its application in risk assessment.
Brandon, EF; Oomen, AG; Rompelberg, CJ; Sips, AJ; van Engelen, JG; Versantvoort, CH, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The compound was hepatotoxic and accelerated the development of chronic renal disease in this strain, an effect that contributed to a marked decrease in the survival of dosed animals."( Carcinogenicity and chronic toxicity of 2,4-toluenediamine in F344 rats.
Cardy, RH, 1979
)
0.26
" With the liver UDS test, discrimination was achieved but the positive effect seen for the carcinogenic isomer was weak and dependent on the method of preparation of the dosing suspensions."( Evaluation of the in vivo genotoxicity of the structural analogues 2,6-diaminotoluene and 2,4-diaminotoluene using the rat micronucleus test and rat liver UDS assay.
George, E; Westmoreland, C, 1991
)
0.5
" Greater than 10% depression in body weight gain occurred in all dosed groups of rats throughout most of the study."( The carcinogenic activity of commercial grade toluene diisocyanate in rats and mice in relation to the metabolism of the 2,4- and 2,6-TDI isomers.
Boorman, GA; Dieter, MP; Huff, JE; Jameson, CW; Matthews, HB, 1990
)
0.28
" The dose-response and correlative relationship between the two macromolecules were investigated over a range of doses (0-250 mg/kg)."( Hemoglobin and DNA adduct formation in Fischer-344 rats exposed to 2,4- and 2,6-toluene diamine.
Froines, JR; La, DK; Wilson, PM, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminotolueneAny member of the class of toluenes carrying one or more amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency75.48570.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency67.12040.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.36420.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID504467
GLI family zinc finger 3Homo sapiens (human)Potency17.98580.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.18380.000221.22318,912.5098AID1259243; AID743063
Smad3Homo sapiens (human)Potency0.56230.00527.809829.0929AID588855
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency21.52070.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.91210.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency7.99050.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency51.29320.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency66.78010.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.70020.000229.305416,493.5996AID1259244; AID1259248; AID743075; AID743077
aryl hydrocarbon receptorHomo sapiens (human)Potency30.00030.000723.06741,258.9301AID651777; AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency24.33650.001628.015177.1139AID1224843
Histone H2A.xCricetulus griseus (Chinese hamster)Potency100.20960.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency50.12470.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency59.61790.000627.21521,122.0200AID651741; AID743219
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency16.77440.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency16.77440.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency2.66030.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (135)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (25.93)18.7374
1990's53 (39.26)18.2507
2000's21 (15.56)29.6817
2010's23 (17.04)24.3611
2020's3 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.85 (24.57)
Research Supply Index4.95 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index41.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (3.57%)6.00%
Case Studies1 (0.71%)4.05%
Observational0 (0.00%)0.25%
Other134 (95.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]